Organic Communications,
Год журнала:
2024,
Номер
3, С. 133 - 143
Опубликована: Авг. 4, 2024
Ulcerative
colitis
(UC)
is
a
chronic
inflammatory
bowel
disease
mainly
affecting
the
colon
and
remains
challenging
to
manage
clinically
with
its
relapsing-remitting
course.Traditional
treatments
for
this
showed
some
drawbacks,
including
systemic
toxicity
ineffective
targeting
of
affected
areas.This
article
introduces
unique
treatment
method
that
uses
mesalazine
(MSZ)-loaded
TPP/Chitosan
nanoparticles
(MSZNP)-embedded
into
bovine
serum
albumin
(BSA)
hydrogels
(MSZNPH)
targeted
intrarectal
medication
delivery.Additionally,
conventional
MSZ
was
integrated
BSA
hydrogel
(MSZH),
then,
MSZH,
MSZNP,
MSZNPH
were
characterized
compared
an
emphasis
on
encapsulation
efficiency,
drug
release
profile,
swelling
behavior.Our
findings
show
composite
technology
may
improve
administration
prolonged
MSZ,
indicating
promising
new
route
UC
therapy
potential
patient
adherence
outcomes.
ACS Nano,
Год журнала:
2024,
Номер
18(50), С. 33792 - 33826
Опубликована: Дек. 3, 2024
Alzheimer's
disease
(AD)
is
a
neurodegenerative
that
causes
memory
loss
and
progressive
permanent
deterioration
of
cognitive
function.
The
most
challenging
issue
in
combating
AD
its
complicated
pathogenesis,
which
includes
the
deposition
amyloid
β
(Aβ)
plaques,
intracellular
hyperphosphorylated
tau
protein,
neurofibrillary
tangles
(NFT),
etc.
Despite
rapid
advancements
mechanistic
research
drug
development
for
AD,
currently
developed
drugs
only
improve
ability
temporarily
relieve
symptoms
but
cannot
prevent
AD.
Moreover,
blood–brain
barrier
(BBB)
creates
huge
to
delivery
brain.
Therefore,
effective
diagnostic
tools
treatments
are
urgently
needed.
In
recent
years,
nanomedicine
has
provided
opportunities
overcome
challenges
limitations
associated
with
traditional
diagnostics
or
treatments.
Various
types
nanoparticles
(NPs)
play
an
essential
role
diagnosis
treatment
acting
as
carriers
targeting
bioavailability
across/bypass
BBB
directly
on
lesions.
This
review
categorizes
different
NPs
summarizes
their
applications
It
also
discusses
clinical
explores
latest
developments
prospects
Pharmaceutics,
Год журнала:
2025,
Номер
17(3), С. 352 - 352
Опубликована: Март 9, 2025
Pharmaceutical
3D
printing,
combined
with
nanomaterials
and
nanodevices,
presents
a
transformative
approach
to
precision
medicine
for
treating
neurological
diseases.
This
technology
enables
the
creation
of
tailored
dosage
forms
controlled
release
profiles,
enhancing
drug
delivery
across
blood−brain
barrier
(BBB).
The
integration
nanoparticles,
such
as
poly
lactic-co-glycolic
acid
(PLGA),
chitosan,
metallic
nanomaterials,
into
3D-printed
scaffolds
improves
treatment
efficacy
by
providing
targeted
prolonged
release.
Recent
advances
have
demonstrated
potential
these
systems
in
conditions
like
Parkinson’s
disease,
epilepsy,
brain
tumors.
Moreover,
printing
allows
multi-drug
combinations
personalized
formulations
that
adapt
individual
patient
needs.
Novel
approaches,
including
stimuli-responsive
systems,
on-demand
dosing,
theragnostics,
provide
new
possibilities
real-time
monitoring
disorders.
Despite
innovations,
challenges
remain
terms
scalability,
regulatory
approval,
long-term
safety.
future
perspectives
this
suggest
its
revolutionize
treatments
offering
patient-specific
therapies,
improved
penetration,
enhanced
outcomes.
review
discusses
current
state,
applications,
nanotechnology
treatment,
highlighting
need
further
research
overcome
existing
challenges.
ACS Applied Materials & Interfaces,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 28, 2025
Electrospun
nanofibers
have
a
number
of
qualities
that
make
them
suitable
choice
for
skin
wound
healing.
Lysophosphatidic
acid
(LPA)
stimulates
the
keratinocytes
and
fibroblasts
to
proliferate,
differentiate,
migrate
enhances
Here,
we
developed
electrospun
scaffolds
contained
in
polycaprolactone
(PCL)
polylactic-co-glycolic
(PLGA).
The
loaded
with
LPA
nanoparticles
retained
porous
nanofiber
structure
showed
better
physicochemical
properties
biocompatibility.
scaffold
continuously
releases
quickly
initiate
cell
signaling
maintain
long-term
anti-inflammatory
activity.
In
this
study,
found
PP
reduces
disordered
collagen
deposition
thickness
newborn
epidermis,
improves
healing,
scar
formation.
Explaining
mechanism
mineralized
tissue
regeneration
inhibited
pyroptosis
keratinocyte,
death
process
induces
inflammation
formation
by
inhibiting
expression
TNF-α
β-catenin
proteins.
Thus,
can
be
potentially
as
therapeutic
avenue
target
Pharmaceutics,
Год журнала:
2025,
Номер
17(4), С. 445 - 445
Опубликована: Март 31, 2025
Background/Objectives.
Central
nervous
system
(CNS)-related
diseases
such
as
Alzheimer’s
and
Parkinson’s,
Attention
Deficit
Hyperactive
Disorder
(ADHD),
stroke,
epilepsy,
migraines
are
leading
causes
of
morbidity
disability
worldwide.
New
solutions
for
drug
delivery
increasingly
needed.
In
this
context,
three-dimensional
(3D)
printing
technology
has
introduced
innovative
alternatives
to
produce
more
efficient
medicines
with
diverse
features,
patterns,
consistencies,
particularly
oral
medications.
Even
though
research
in
area
is
growing
rapidly,
no
study
thoroughly
analyzed
3D
progress
the
CNS.
To
fill
gap
pursues
determine
a
technological
landscape
field.
Methods.
For
aim,
Competitive
Technology
Intelligence
(CTI)
methodology
was
applied,
examining
747
publications
from
1
January
2019
20
May
2024
published
Scopus
database.
Results.
The
main
advances
identified
comprise
six
categories:
techniques,
characteristics
applications,
materials,
design
factors,
user
acceptance,
quality
processes.
FDM
technique
pharmaceutical
use.
applications
include
pills,
polypills,
caplets,
gel
caps,
multitablets,
orodispersible
films,
tablets,
featuring
external
patterns
internal
structures
one
or
active
substances.
Insights
show
that
most
utilized
materials
thermoplastic
polymers
like
PLA,
PVA,
PCL,
ABS,
HIPS.
A
novel
factor
involves
release
using
compartments
varying
thicknesses
volumes
core.
Additionally,
specialized
software
have
enabled
creation
highly
complex
designs.
acceptance
category,
drugs
dosages
tailored
specific
needs
preferences
neurological
patients.
Finally,
aspect,
precision
Active
Pharmaceutical
Ingredient
(API)
dosage
controlled-release
mechanisms
critical,
given
narrow
margin
between
therapeutic
doses
toxicity
CNS
diseases.
Conclusions.
Revealing
these
advancements
allows
researchers,
academics,
decision-makers
identify
opportunities
allocate
resources
efficiently,
promising
enhanced
medicaments
health
well-being
individuals
suffering
disorders.
